Tune Therapeutics

📍 Durham, United States🗓 Founded 2020👥 92 employees💰 Last funded Mar 2023
Biotechnology🌐 tunetx.com
Website LinkedIn
The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Tune Therapeutics?
Tune Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Tune Therapeutics last raise funding?
The most recent investment in Tune Therapeutics recorded on gritt.io was in March 2023.
When was Tune Therapeutics founded?
Tune Therapeutics was founded in 2020.
What industry is Tune Therapeutics in?
Tune Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Tune Therapeutics based?
Tune Therapeutics is headquartered in Durham, United States.